CG Oncology, Inc. CGON
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +55.78%
- 1 year
- +52.30%
- Open
- 63.02
- Prev close
- 63.47
- Mkt cap
- 5.73B
- Vol
- 870.33K
- Avg vol
- 868.03K
- EPS
- -2.69
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 60.63
- High
- 65.55
- Forward P/E
- -21.41
- Beta
- 0.28
- Short ratio
- 8.13
- Inst. own
- 113.45%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 13, 2026
- 50-d avg
- 69.69
- 200-d avg
- 65.86
- 1y target
- 91.08
News
5 days ago seekingalpha.com
CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy
CG Oncology is well-positioned to enter a de-risked NMIBC market with cretostimogene, offering a clean tolerability profile and randomized Phase 3 data. CGON's $1B+ cash position funds operations…
1 week ago defenseworld.net
CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 1,000 Shares of Stock
CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) Director Leonard Post sold 1,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of…
2 weeks ago globenewswire.com
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical…
2 weeks ago gurufocus.com
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC
2 weeks ago prnewswire.com
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached…
1 month ago defenseworld.net
Insider Selling: CG Oncology (NASDAQ:CGON) Director Sells $72,980.00 in Stock
CG Oncology, Inc. (NASDAQ: CGON - Get Free Report) Director Leonard Post sold 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an…
1 month ago seekingalpha.com
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago defenseworld.net
23,000 Shares in CG Oncology, Inc. $CGON Purchased by Jupiter Topco LLC
Jupiter Topco LLC purchased a new stake in shares of CG Oncology, Inc. (NASDAQ: CGON) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission…
1 month ago schaeffersresearch.com
15 Stocks to Watch With Short Squeeze Potential
Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.
2 months ago globenewswire.com
CG Oncology to Present at Upcoming Investor Conferences in September
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat…
2 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 months ago prnewswire.com
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached…
2 months ago seekingalpha.com
CG Oncology: Circling Back After Huge Rally
CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and…
2 months ago defenseworld.net
CG Oncology, Inc. $CGON Shares Bought by California State Teachers Retirement System
California State Teachers Retirement System increased its stake in CG Oncology, Inc. (NASDAQ: CGON) by 23.6% during the undefined quarter, according to the company in its most recent 13F filing with…
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and lowers the price target from $81 to $79.
-
2 months ago benzinga.com
Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85
Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $82 to $85.
-
2 months ago benzinga.com
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $82 to $85.
2 months ago zacks.com
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.54 per share a year ago.
-
2 months ago benzinga.com
CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate
CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.67) by 34.33 percent. This is a 66.67 percent decrease over losses of…
2 months ago globenewswire.com
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
3 months ago globenewswire.com
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached…
3 months ago globenewswire.com
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder…
-
3 months ago benzinga.com
ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Motions For New Trial, Judgement; Co. Seeks To Recover Assets' Value Sold to CG Oncology Under 2010 Deal
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a matter…
3 months ago zacks.com
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
4 months ago marketbeat.com
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
CG Oncology NASDAQ: CGON Chief Executive Officer Arthur outlined the company's upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global…
4 months ago seekingalpha.com
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $100 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $100 price target.
-
5 months ago benzinga.com
CG Oncology Reports First Results From CORE‑008 Cohort CX Phase 2 Trial
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively- High-Grade - EFS in the overall…
-
5 months ago benzinga.com
Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $82
Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $77 to $82.
-
5 months ago benzinga.com
JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $96
JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $91 to $96.
5 months ago benzinga.com
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings
CG Oncology (NASDAQ:CGON) reported mixed results for Q1, with losses of 71 cents per share and sales of $1.083 million. Analysts have adjusted price targets.
-
5 months ago benzinga.com
RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $81
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $79 to $81.
-
5 months ago benzinga.com
Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $77
Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $75 to $77.
-
5 months ago benzinga.com
Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $80
Wedbush analyst Yun Zhong maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $77 to $80.
-
5 months ago benzinga.com
CG Oncology Q1 EPS $(0.71) Misses $(0.57) Estimate, Sales $1.083M Beat $493.182K Estimate
CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.57) by 24.56 percent. This is a 57.78 percent decrease over losses of…
-
6 months ago benzinga.com
RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $79
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $73 to $79.
-
6 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $100
HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $80 to $100.
8 months ago benzinga.com
What Analysts Are Saying About CG Oncology Stock
What Analysts Are Saying About CG Oncology Stock
-
8 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on CG Oncology, Raises Price Target to $80
HC Wainwright & Co. analyst Andres Y. Maldonado maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $75 to $80.
8 months ago benzinga.com
CG Oncology Q4 Earnings Report: What Investors Need to Know
CG Oncology Q4 Earnings Report: What Investors Need to Know
-
8 months ago benzinga.com
CG Oncology Q4 EPS $(0.51) Beats $(0.59) Estimate, Sales $2.322M Beat $1.641M Estimate
CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.59) by 13.56 percent. This is a 10.87 percent decrease over losses of $(0.46)…
8 months ago benzinga.com
Expert Outlook: CG Oncology Through The Eyes Of 7 Analysts
Expert Outlook: CG Oncology Through The Eyes Of 7 Analysts
-
8 months ago benzinga.com
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $75
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $66 to $75.
-
9 months ago benzinga.com
What Analysts Are Saying About CG Oncology Stock
What Analysts Are Saying About CG Oncology Stock
-
9 months ago benzinga.com
RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $73
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $61 to $73.
-
9 months ago benzinga.com
Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $70
Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $55 to $70.
-
9 months ago benzinga.com
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $66
Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $62 to $66.
9 months ago benzinga.com
Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January
Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
9 months ago benzinga.com
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday
CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday